-
WAIT FOR SUGGESTIONS BY CATEGORY
OR CONTINUE TYPING IN YOUR KEYWORDSENTER ONE OR MULTIPLE KEYWORDS &
PRESS THE SEARCH BUTTON -
-
Search
-
Favorites
-
Advanced Minimize
-
-
-
-
Clear
- Chairs : Jean-Jacques Kiladjian, Ross Levine, Jyoti Nangalia
- April 26-28, 2024 - Mandelieu-La Napoule, France
- #ESHMPN2024
Stay tuned: on-demand programme
opens to all on July 28th, 2024
SCIENTIFIC TOPICS:
- Molecular pathogenesis of MPNs
- Novel MPN therapeutics targets
- MPN clonal evolution
- MPN models and pathogenesis/therapeutic studies
- New therapies and challenges in the management of MPN
- Update on therapeutic approaches in MPN
- Update in MPN diagnostics
- CALR Mutations in MPN Pathogenesis and Therapy
- Polycythemias
FACULTY MEMBERS:
Lionel Adès (Paris), Prithviraj Bose (Houston), Grant Challen (St Louis), Edwin Chen (Canterbury), Shannon E. Elf (Salt Lake City), Angela Fleischman (Irvine), Betty Gardie (Nantes), Stéphane Giraudier (Paris), Ana Godfrey (Cambridge), Tony Green (Cambridge), Claire Harrison (London), Ronald Hoffman (New York), Gerwin Huls (Groningen), Chloé James (Bordeaux), Jean-Jacques Kiladjian (Paris), Ross Levine (New York), Damien Luque Paz (Angers), John Mascarenhas (New York), Adam Mead (Oxford), Ruben Mesa (Charlotte), Ann Mullaly (London), Jyoti Nangalia (Cambridge), Isabelle Plo (Villejuif), Bethan Psaila (Oxford), Raajit Rampal (New York), Andreas Reiter (Mannheim), Dan Royston (Oxford), Alessandro Vannucchi (Florence)
ABOUT THE CONFERENCE:
New insights into the molecular pathogenesis, classification, and management of patients with Myeloproliferative Neoplasms (MPN) have arisen at increasing pace during the past years. This International Conference brings together scientists and clinicians to present and discuss new data on the cellular and molecular biology of these disorders as well as their diagnosis and treatment.
- Chairs : Pierre Fenaux, Katharina Götze, Mikkael Sekeres
- April 12-14, 2024 - Budapest, Hungary
- #ESHMDS2024
Stay tuned: on-demand programme
opens to all on July 14th, 2024
SCIENTIFIC TOPICS:
- The sinister origins of MDS
- The interplay between MDS, inflammatory, and immune abnormalities
- What’s in a name? Classifying MDS
- New tools to explore MDS
- Special populations
- Treatment of lower-risk MDS
- Treatment of higher-risk MDS
- Transplantation
- Clinical trials in MDS/CMML: cooperative groups
FACULTY MEMBERS:
Lionel Adès (Paris), Didier Blaise (Marseille), Rena Buckstein (Toronto), Maria Diez Campelo (Salamanca), Pierre Fenaux (Paris), Michaela Fontenay (Paris), Guillermo Garcia-Manero (Houston), Aristoteles Giagounidis (Düsseldorf), Katharina Götze (Munich), Claudia Haferlach (Munich), Torsten Haferlach (Munich), Eva Hellström-Lindberg (Stockholm), Shahram Kordasti (London), Jaroslaw Maciejewski (Cleveland), Carsten Marr (Munich), Klaus Metzeler (Leipzig), Aziz Nazha (New Jersey), Valeria Santini (Florence), Marie Sebert (Paris), Mikkael Sekeres (Miami), Dorothée Selimoglu-Bluet (Paris), Amer Zeidan (New Haven)
ABOUT THE CONFERENCE:
#ESHMDS2024 proposes a programme of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field. It is open to an international audience of biologists and clinicians, including those still in-training. This translational research conference will bring together biologists and clinicians with an interest in Myelodysplastic Syndromes (MDS) in order to explore the most recent advances in the understanding of the pathogenesis and clinical behavior of the disease.
- Chairs: Jennifer Brown, Paolo Ghia, Michael Hallek
- March 8-10, 2024 - Vienna, Austria
- #ESHCLL2024
Stay tuned: on-demand programme
opens to all on 10th, 2024
SCIENTIFIC TOPICS:
- CLL disease progression
- Richters syndrome
- Biomarkers: where do we stand?
- Targeting the microenvironment in CLL
- What is the best time-limited therapy
- BTK inhibitors
- Small molecule resistance
- Next generation therapies
- The future: other targets
FACULTY MEMBERS:
Rafet Basar (Houston), James Blachly (Columbus), Jennifer Brown (Boston), Elias Campo (Barcelona), Matthew Davids (Boston), Barbara Eichhorst (Cologne), Toby Eyre (Oxford), Lukas Frenzel (Cologne), Richard Furman (New York), Paolo Ghia (Milan), Michael Hallek (Cologne), Arnon Kater (Amsterdam), Hien Nguyen (Cologne), Carsten Niemann (Copenhagen), Sarka Pospilova (Brno), Andy Rawstron (Leeds), Pauline Robbe (Oxford), Martina Seiffert (Heidelberg), Tanya Siddiqi (Duarte), Susan Slager (Rochester), Kostas Stamatopoulos (Thessaloniki), Justin Taylor (Miami), Elisa Ten Hacken (New York), William Wierda (Houston), Adrian Wiestner (Bethesda), Jennifer Woyach (Columbus)
ABOUT THE CONFERENCE:
#ESHCLL2024 proposes a programme of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field. It is open to an international audience of biologists and clinicians, including those still in-training. This translational research conference will bring together biologists and clinicians with an interest in Chronic Lymphocytic Leukaemia (CLL) in order to explore the most recent advances in the understanding of the pathogenesis and clinical behaviour of the disease.
- Chairs: Hervé Dombret, Gert Ossenkoppele, Christoph Röllig, Wendy Stock
- March 1-3, 2024 - Stockholm, Sweden
- #ESHAL2024
On-demand scientific programme
reserved to participants
SCIENTIFIC TOPICS:
- Diagnosis and treatment of rare diseases
- Novel treatments
- Dilemmas in AML
- Debate: MRD conversion before alloSCT
- Innovative trial designs to accelerate advances in leukaemia
- Immunotherapy in AML and ALL
- VenAza or intensive chemo as 1L treatment before allo HCT
- Debate: Transplant is no longer first line approach to Ph+ ALL
- Leukaemia treatment challenges
- Clonal haematopoiesis and germline predisposition
FACULTY MEMBERS:
Lionel Ades (Paris), Lucie Biard (Paris), Nicolas Boissel (Paris), Yves Chalandon (Geneva), Sabina Chiaretti (Rome), Charlie Craddock (Birmingham), Hervé Dombret (Paris), Michael Drazer (Chicago), Jordi Esteve (Barcelona), Nicola Gökbuget (Frankfurt), Chris Hourigan (Bethesda), Gerwin Huls (Groningen), Andrew Lane (Boston), Mark Litzow (Rochester), Lori Muffly (Stanford), Kristen O’Dwyer (Rochester), Etan Orgel (Los Angeles), Gert Ossenkoppele (Amsterdam), Megan Othus (Seattle), Alexander Perl (Philadelphia), Keith Pratz (Philadelphia), Marc Raaijmakers (Rotterdam), Christoph Röllig (Dresden), David Sallman (Tampa), Caner Saygin (Chicago), Judith Schaffrath (Dresden), Marie Sebert (Paris), Wendy Stock (Chicago), Richard Stone (Boston), Marion Subklewe (Munich), Adriano Venditti (Rome), Eunice Wang (Buffalo), Andrew Wei (Melbourne), Matthew J. Wieduwilt (Oklahoma City), Agnieszka Wierzbowska (Lodz), Daniel Wolff (Regensburg)
On-demand programme supported by Daiichi*
*ESH Conference programmes are developed in strict scientific independence with no input from corporate sponsors.
ABOUT THE CONFERENCE:
The programme of this conference includes genomic analysis and cutting-edge technics in routine diagnosis, targeted therapies and standard of care treatments allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes.
- Chairs: Hartmut Döhner, Bob Löwenberg, Martin Tallman
- October 29-31, 2023 - Estoril, Portugal
- #ESHAML2023
SCIENTIFIC TOPICS:
- Preleukemic hematopoiesis and clonal diversity
- Preleukemic conditions and predisposition
- Epigenetics
- MDS / Secondary leukemia
- Immune targeting
- Therapeutic targeting
FACULTY MEMBERS:
Lars Bullinger (Berlin), Katherine R. Calvo (Bethesda), Courtney Dinardo (Houston), John DiPersio (Saint Louis), Hartmut Döhner (Ulm), Konstanze Döhner (Ulm), Hervé Dombret (Paris), Benjamin Ebert (Boston), Saar Gill (Philadelphia), Robert Hasserjian (Boston), Raphaël Itzykson (Paris), Alex Kentsis (New York), Coleman Lindsley (Boston), Bob Löwenberg (Rotterdam), Ravi Majeti (Stanford), Linde Miles (Cincinnati), Adrian Ochsenbein (Bern), Alexander Perl (Philadelphia), Sergio Rutella (Nottingham), Mathijs Sanders (Rotterdam), Philipp Staber (Vienna), Eytan Stein (New York), Martin Tallman (Chicago), Hannah Uckelmann (Frankfurt), Peter Valk (Rotterdam), George Vassiliou (Cambridge), Paresh Vyas (Oxford), Matthew Walter (Saint Louis), Eunice Wang (Buffalo), Caroline Watson (Cambridge)
ABOUT THE CONFERENCE:
The cutting-edge program of the conference deals with the molecular and functional features of leukemic stem cells and their interaction with the microenvironment, the role of somatic and germ-line mutations and epigenetic alterations in the biology of AML, the genomics of leukemogenesis, advances in molecular diagnostics and developmental therapeutics with a focus on molecular and immunotherapeutic targeted therapeutics.
- Chairs: Michael Hallek, Georg Lenz, Laurie Sehn, Louis Staudt
- October 20-22, 2023 - Estoril, Portugal
- #ESHLYMPHOID2023
SCIENTIFIC TOPICS:
- Biology of diffuse large B cell lymphoma subtypes II
- Novel molecular lymphoma subtypes
- Epigenetic and genetic regulation of clonal lymphoma evolution
- Lymphoma cell interactions in the tumor microenvironment
- Monoclonal antibodies & non-cellular immune therapies
- Cellular immune therapies
- Small molecular pathway inhibitors
- Combination therapies
- Use of CT DNA for diagnostic and therapeutic monitoring
FACULTY MEMBERS:
Stefan Alig (Stanford), Ash Alizadeh (Stanford), Silvia Bea (Barcelona), Catherine Bollard (Washington), Riccardo Dalla-Favera (New York), Alexey Danilov (Duarte), Silvia Deaglio (Turin), Moritz Fürstenau (Cologne), Paolo Ghia (Milan), Michael Hallek (Cologne), Daniel Hodson (Cambridge), Martin Hutchings (Copenhagen), Javeed Iqbal (Omaha), Daniel Krappmann (Neuherberg), Georg Lenz (Muenster), Ari Melnick (New York), David Miklos (Stanford), Mark Roschewski (Bethesda), Gilles Salles (New York), David Scott (Vancouver), Laurie Sehn (Vancouver), Karin Tarte (Rennes), Jason Westin (Houston), Wyndham Wilson (San Francisco), Catherine Wu (Boston)
ABOUT THE CONFERENCE:
This leading-edge translational research conference will address the rapidly evolving field of lymphoid malignancies, including T- and B-cell lymphomas, and chronic lymphocytic leukaemia (CLL), from molecular pathogenesis to state-of-the-art treatment and future perspectives.
- Chairs: Jorge Cortes, Tim P. Hughes, Daniela S. Krause
- October 6-8, 2023 - Mandelieu-La Napoule, France
- #ESHCML2023
ABOUT THE PROGRAM:
The program includes the latest in research in chronic myeloid leukemia, including basic, translational and clinical research with an emphasis on open discussion among participants. There are also scientific workshops to discuss the latest technologies of value in CML research, and clinical symposia with focus on topics of interest to the CML community. There are special lectures on topics of general interest to the CML community from lead experts in their field. The program is designed to encourage discussion and collaboration among participants, presenters and attendees.
The meeting brings together experts in CML research and practice from all over the world, giving the opportunities to all attendees to interact, exchange ideas, review the most recent research and future plans for additional studies. The open interaction format provides an excellent forum to encourage collaborations and open discussion.
CO-ORGANIZERS:
Ravi Bhatia, Tim Brümmendorf, Mhairi Copland, Michael Deininger, Olivier Hantschel, Vignir Helgason, Sin Tiong Ong, Jerry Radich, Delphine Réa
ADVISORY COMMITTEE:
Jane Apperley, Susan Branford, Carlo Gambacorti-Passerini, François Guilhot, Rüdiger Hehlmann, Pierre Laneuville, François-Xavier Mahon, Danilo Perrotti, Giuseppe Saglio, Charles Schiffer, Simona Soverini, Peter Valent, Rick Van Etten
- Chairs: Ulrich Jäger, Marie José Kersten, Loretta Nastoupil
- September 29 - October 01, 2023 - Berlin, Germany
- #ESHCART2023
SCIENTIFIC TOPICS:
- Non-hodgkin lymphoma (NHL)
- Multiple myeloma
- Novel indications CAR T-cell therapy
- Managing toxicity of CAR-T and bispecific antibody treatment
- Real world data CAR-T
- Life after CAR T-cell therapy
FACULTY MEMBERS:
Jeremy Abramson (Boston), Veronika Bachanova (Minneapolis), Pere Barba (Barcelona), André Baruchel (Paris), Natacha Bolanos (Madrid), Elizabeth Budde (Duarte), Jonathan Clark (Loosdrecht), Kate Cwynarski (London) , Stephan Fricke (Leipzig), Michael Green (Houston), Martin Hutchings (Copenhagen), Gloria Iacoboni (Barcelona), Ulrich Jäger (Vienna), Marie José Kersten (Amsterdam), Sebastian Klobuch (Amsterdam), Andrea Kuhnl (London), Frederick Locke (Tampa), Maria-Victoria Mateos (Salamanca), Monique Minnema (Utrecht), Loretta Nastoupil (Houston), Elise Pennings (Amsterdam), Kai Rejeski (Munich), Claire Roddie (London), Lukas Scheller (Würzburg), Hans Scheurer (Amsterdam), Anna Sureda (Barcelona), Catherine Thieblemont (Paris), Frederick Thielen (Rotterdam), Alvaro Urbano-Ispizua (Barcelona), Marcel Van Den Brink (New York), Tom Van Meerten (Groningen), Johannes Waldschmidt (Würzburg)
ABOUT THE CONFERENCE:
CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies. The programme of this conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies are discussed.
- Chairs: Jan Cools, Hervé Dombret, Adele Fielding, Mark Litzow
- May 19-21, 2023 - Berlin, Germany
- #ESHALL2023
SCIENTIFIC TOPICS:
- KMT2A-rearranged ALL
- Advances in Ph-like ALL
- Revisiting specific ALL subsets
- New biological insights in ALL
- Ph-positive ALL
- Therapeutic Challenges in Childhood ALL
- Antibody-based ALL Therapies
- CAR T-cells & Stem Cell Transplantation
- Precision Medicine in ALL
FACULTY MEMBERS:
Guillaume P. Andrieu, André Baruchel, Judith Boer, Nicolas Boissel, Emmanuelle Clappier, Jan Cools, Monique Den Boer, Hervé Dombret, Adele Fielding, Claudia Haferlach, Stephen P. Hunger, Nitin Jain, Rathana Kim, Federico Lussana, Paul Maciocia, Takahiro Maeda, Jules Meijerink, Charles Mullighan, Katrin Ottersbach, Oliver Ottmann, Jae Park, Marie Passet, Anita Rijneveld, Philippe Rousselot, Dennis Schewe, Nicholas J. Short, Ronald Stam, Eytan M. Stein, Janine Stutterheim, Sarah Tasian, Jun J. Yang
ABOUT THE CONFERENCE:
Major recent advances in the knowledge of the biological underpinning of acute lymphoblastic leukaemia (ALL) include the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, the identification of new potentially druggable disease subsets and the discovery of predisposing, preleukaemic events.
What's new
By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).
USER TERMS AND CONDITIONS | PRIVACY POLICY
Accept Terms & all Cookies
MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.
Performance Cookies
Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.
Google Analytics and Google Tag Manager embedded tracking functionalities are used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG's features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.